Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and
Wendy I Sligl1, Leyla Asadi, Dean T Eurich
11Division of Critical Care Medicine, University of Alberta, Edmonton, AB, Canada. 2Division of Infectious Diseases, University of Alberta, Edmonton, AB, Canada. 3Department of Public Health Sciences, School of Public Health, University of Alberta, Edmonton, AB, Canada. 4John W. Scott Health Sciences Library, University of Alberta, Edmonton, AB, Canada. 5Department of Medicine, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada. 6Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Objective:
Some studies suggest better outcomes with macrolide therapy for critically ill patients with community-acquired pneumonia. To further explore this, we performed a systematic review of studies with mortality endpoints that compared macrolide therapy with other regimens in critically ill patients with community-acquired pneumonia.
Data Sources:
Studies were identified via electronic databases, grey literature, and conference proceedings through May 2013.
Study Selection:
Using prespecified criteria, two reviewers selected studies; studies of outpatients and hospitalized noncritically ill patients were excluded.
Data Extraction:
Two reviewers extracted data and evaluated bias using the Newcastle-Ottawa Scale. Random effects models were used to generate pooled risk ratios and evaluate heterogeneity (I).
Data Synthesis:
Twenty-eight observational studies (no randomized control trials) were included. Average age ranged from 58 to 78 years and 14-49% were women. In our primary analysis of 9,850 patients, macrolide use was associated with statistically significant lower mortality compared with nonmacrolides (21% [846 of 4,036 patients] vs 24% [1,369 of 5,814]; risk ratio, 0.82; 95% CI, 0.70-0.97; p = 0.02; I = 63%). When macrolide monotherapy was excluded, the macrolide mortality benefit was maintained (21% [737 of 3,447 patients] vs 23% [1,245 of 5,425]; risk ratio, 0.84; 95% CI, 0.71-1.00; p = 0.05; I = 60%). When broadly guideline-concordant regimens were compared, there was a trend to improved mortality and heterogeneity was reduced (20% [511 of 2,561 patients] mortality with beta-lactam/macrolide therapy vs 23% [386 of 1,680] with beta-lactam/fluoroquinolone; risk ratio, 0.83; 95% CI, 0.67-1.03; p = 0.09; I = 25%). When adjusted risk estimates were pooled from eight studies, macrolide therapy was still associated with a significant reduction in mortality (risk ratio, 0.75; 95% CI, 0.58-0.96; p = 0.02; I = 57%).
Conclusions:
In observational studies of almost 10,000 critically ill patients with community-acquired pneumonia, macrolide use was associated with a significant 18% relative (3% absolute) reduction in mortality compared with nonmacrolide therapies. After pooling data from studies that provided adjusted risk estimates, an even larger mortality reduction was observed. These results suggest that macrolides be considered first-line combination treatment in critically ill patients with community-acquired pneumonia and support current guidelines.
Insights
Macrolide therapy significantly reduced mortality in critically ill patients with community-acquired pneumonia. This systematic review found macrolides to be a beneficial first-line treatment option.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Pharmacology
Background:
- Community-acquired pneumonia (CAP) is a leading cause of critical illness.
- Macrolide antibiotics are suggested to improve outcomes in severe CAP.
- Evidence comparing macrolides with other treatments in critically ill patients requires systematic evaluation.
Purpose of the Study:
- To systematically review studies evaluating macrolide therapy versus other regimens for critically ill CAP patients.
- To assess the impact of macrolide use on mortality endpoints in this population.
Main Methods:
- Systematic review and meta-analysis of observational studies (no RCTs) identified through May 2013.
- Two reviewers selected studies, extracted data, and assessed bias using the Newcastle-Ottawa Scale.
- Random effects models were used to calculate pooled risk ratios and assess heterogeneity.
Main Results:
- Twenty-eight observational studies including 9,850 critically ill patients were analyzed.
- Macrolide use was associated with a statistically significant reduction in mortality (RR, 0.82; 95% CI, 0.70-0.97).
- Adjusted risk estimates from eight studies showed an even greater mortality reduction (RR, 0.75; 95% CI, 0.58-0.96).
Conclusions:
- Macrolide therapy in critically ill CAP patients was associated with a significant 18% relative reduction in mortality.
- Results support considering macrolides as first-line combination therapy for severe CAP.
- Findings align with and reinforce current clinical guidelines for CAP management.
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia III: Complications and Assessment
01:25Mechanism of Antibiotic Resistance in MRSA
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia I: Introduction
01:25Clinical Significance of Antibiotic Resistance